Artiva Biotherapeutics
ARTV | NASDAQ
$3.96
-$0.05 (-1.25%)
At close: Nov 16, 2026, 4:00 PM ET
$3.94
-$0.02 (-0.51%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-1.25%
(1D)No price chart data available for 1D timeframe.
Rating
20.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #985/1021 (Top 96%)
Key Statistics
Market Data
Market Cap $195.75M
1D Range
3.93 4.06
52W Range
3.07 13.39
Valuation (TTM)
PE -1.32
PB 0.61
EV/EBITDA 1.20
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $4.00
Cash Flow
FCF Yield -44.2%
SBC Adj. FCF Yield -48.3%
SBC Impact -9.1%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
-10.7%
Dil EPS 3Y | 5Y -1.9% |
-1.7%
FCF 3Y | 5Y -23.6% |
-23.7%
Returns
ROA -28.6%
ROE -45.3%
ROIC -31.9%
Financial Health
Net Cash
$319.1M
Current Ratio 19.88
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and...
Sector Healthcare
Industry Biotechnology
Employees 115
IPO Date Jul 19, 2024
Website www.artivabio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Hold
Price Target
$4.00
Upside
+1.01%
Buy (2)
Hold (3)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ARTV